How we grade evidence Glossary CBG Monograph

Side by side

CBGV vs CBG

Q: Is there human evidence for CBGV or CBG?

Barely any. Controlled human data on CBG are scarce, and not one controlled human trial of CBGV appears in our registry. CBG's evidence base is mostly cells and animals; CBGV lacks even that. For now, what either does in people is catalogue in progress. (Not medical advice.) Low (CBG) · No primary evidence (CBGV) · no establishing human trial in our registry · catalogue in progress Evidence grade: Low.

Q: Are CBGV and CBG intoxicating, and are they legal?

CBG is non-intoxicating, and CBGV has no known intoxicating effect, though it has not been characterised in humans. On the law, both generally sit within the US hemp framework: under the 2018 Farm Bill, derivatives with no more than 0.3% Δ9-THC are broadly legal at the federal level, while state and product-class rules vary. Not legal advice. Grade: Established (CBG non-intoxicating) · Legal snapshot: dated and jurisdiction-specific; check local law Evidence grade: Established.

CBGV: Chemical identity Established; what it does Low / catalogue in progress
CBG: Chemical identity Established; lab receptor data Demonstrated · in vitro (Cascio 2010; De Petrocellis 2011); a mouse colitis study Emerging · preclinical (Borrelli 2013); benefits in people Low

From the evidence status row of the table below.

Shorten CBG's side chain from five carbons to three and you get CBGV. Cannabigerol (CBG) carries a pentyl tail; its "varin" relative, cannabigerovarin or CBGV, carries a propyl chain on the same core, which makes the formulas C19H28O2 for CBGV and C21H32O2 for CBG. On paper the difference is small. In the research record it is enormous: verified lab work maps how CBG acts on several receptors, while almost nothing is known about CBGV's pharmacology (catalogue in progress).

That gap matters to anyone putting CBGV in a product. The shared skeleton makes it tempting to borrow CBG's research for the smaller molecule, and the evidence leaves that move without support.

How to read this. What each molecule is, whether it intoxicates and what it does in laboratory (in-vitro) tests are verified and graded. Statements on effects, benefits, or uses come from manufacturers, media or early research, and CBG Atlas reports them without adopting them. A grade chip opens /evidence, where the grading method is set out. Not medical or legal advice. The full disclaimer sits at the foot.

Side by side

Line the two up and they agree on almost everything chemical, down to the cannabigerol scaffold. Below the formula row they part company. CBG has been studied in vitro; CBGV has barely been characterised.

	CBGV	CBG
Full name	CBGVCannabigerovarin; CBG's propyl, or "varin", counterpart	CBGCannabigerol, sold as "the mother cannabinoid"
Formula / CAS / CID	CBGVC19H28O2 / 55824-11-8 / CID 59444407	CBGC21H32O2 / 25654-31-3 / CID 5315659
Intoxicating?	CBGVNot known to be; no human study has checked Low	CBGNo Established
General legal status	CBGVFalls under the hemp framework (≤0.3% Δ9-THC), broadly legal federally in the US under the 2018 Farm Bill; rules vary by state and product class. Not legal advice.	CBGThe same hemp framework (≤0.3% Δ9-THC); rules vary by state. Not legal advice.
Commonly marketed for (attributed; not our claim)	CBGVAppears in blends of minor and "varin" cannabinoids (marketed use); effects not established; catalogue in progress	CBGMarketed for focus, calm and gut comfort (claims attributed to sellers); little human evidence
Evidence status (graded)	CBGVChemical identity Established; what it does Low / catalogue in progress	CBGChemical identity Established; lab receptor data Demonstrated · in vitro (Cascio 2010; De Petrocellis 2011); a mouse colitis study Emerging · preclinical (Borrelli 2013); benefits in people Low

Figure P · targets side by side

CBGV and CBG at six targets: what our registry records, and where it records nothing

How to read a cell: An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
CB1 cannabinoid receptor: CBGV: no graded interaction in our registry. CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010.
CB2 cannabinoid receptor: CBGV: no graded interaction in our registry. CBG: no graded interaction in our registry.
α2-adrenoceptor: CBGV: no graded interaction in our registry. CBG: activates (agonist; drawn as a chevron), in vitro grade: Demonstrated study type: In vitro Cascio 2010.
5-HT1A serotonin receptor: CBGV: no graded interaction in our registry. CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010.
TRPV1 and TRPV2 ion channels: CBGV: no graded interaction in our registry. CBG: activates, then desensitises (agonist, then desensitiser; drawn as a chevron with a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011.
TRPM8 ion channel: CBGV: no graded interaction in our registry. CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011.

An oxblood frame is a registry record measured in receptors, cells or tissue, which is what in vitro means, with the direction as a glyph: a bar blocks, a chevron activates, a chevron with a bar activates and then desensitises, two bars damp activation. A dashed frame means the registry holds no graded interaction there, which is not the same as evidence of none. None of this is an effect in people, and none of it is a dose. CBGV has no receptor-level record in our registry at any of the six targets: the registry is CBG-centred, and the empty column says so. Sources: Cascio 2010, De Petrocellis 2011. CBG's record at researcher depth is on the monograph's target map; the receptors themselves are drawn on the ECS map →

What the evidence establishes

CBG's record is thin where people are concerned, and it still looks rich beside CBGV's. Verified studies give CBG a defined in-vitro receptor profile and one preclinical signal from an animal model. CBGV is well defined as a chemical and hardly studied beyond that. For a label, the consequence is simple: CBG's research belongs to CBG.

One side chain separates them. CBGV is the varin analog of CBG, with a propyl (three-carbon) chain where CBG has a pentyl (five-carbon) one. On the shared cannabigerol scaffold that works out to C19H28O2 for CBGV and C21H32O2 for CBG. Established · chemical identity.
CBG is non-intoxicating. The documentation on that point is solid Established. CBGV has no known intoxicating effect either, though nobody has formally characterised it in humans Low · catalogue in progress.
CBG's receptor targets are mapped in vitro. In lab assays, Cascio 2010 found CBG switches on the α2-adrenoceptor (agonist), blocks the 5-HT1A serotonin receptor (antagonist) and competes at the CB1 receptor (competitive antagonist). De Petrocellis 2011 added TRP channels: CBG desensitises TRPV1 and TRPV2 and antagonises TRPM8. All of it is lab mechanism, a map of what the molecule touches in a dish, and none of it has been shown to benefit people. Demonstrated · in vitro.

> ⚠ Blood-pressure / cardiovascular caution. Because CBG acts on the α2-adrenoceptor — a receptor central to blood-pressure regulation — its cardiovascular effects in people are not characterised. Anyone with blood-pressure concerns, or taking blood-pressure or other cardiovascular medication, should be cautious and consult a clinician before use. (Not medical advice.)

One animal model shows a preclinical anti-inflammatory signal. In a mouse (murine) model of colitis, CBG was reported to reduce inflammation (Borrelli 2013), an animal finding, not established in humans. Emerging · preclinical.
CBGV's pharmacology is catalogue in progress. The verified record holds neither a receptor profile nor human data for CBGV, and the effects it is sold on are attributed to sellers, not established. Low · catalogue in progress.
Nobody has compared them directly. Our registry holds no head-to-head data, and a similar structure is not evidence of similar activity, because a change in side-chain length can change how a molecule behaves. The belief that CBGV mirrors CBG rests on resemblance alone. The comparison simply hasn't been run, so the question stays open in both directions. No primary evidence · catalogue in progress.

Common questions

CBGV vs CBG — what's the difference?

Side-chain length, and a far bigger difference in evidence. Cannabigerovarin (CBGV) is cannabigerol (CBG) with its five-carbon side chain cut to a three-carbon propyl, the "varin" pattern, which makes the formulas C19H28O2 and C21H32O2 Established. Lab studies have mapped CBG's receptor activity, while CBGV's pharmacology is catalogue in progress, so the chemistry is where the likeness stops.

Grade: Established (identity) · CBGV pharmacology catalogue in progress

Does CBGV do the same thing as CBG?

That is not established, and assuming it does is a gamble. Shortening a side chain can alter a molecule's activity, and nobody has profiled CBGV's receptors or effects the way CBG's have been profiled. Marketing that says "CBGV works like CBG" is trading on family resemblance, an assumption rather than a finding Low · / catalogue in progress. (Not medical advice.)

No primary evidence (equivalence: the comparison has never been run) · CBGV catalogue in progress

What does the evidence actually show for CBG?

Mostly laboratory findings, plus one animal study. Lab work (Cascio 2010) shows CBG activating the α2-adrenoceptor while blocking 5-HT1A and CB1, and De Petrocellis 2011 adds effects on TRP channels Demonstrated · in vitro. In a mouse model of colitis, Borrelli 2013 reported less inflammation Emerging · preclinical. None of it has been shown in people.

Grade: Demonstrated (in vitro) · Emerging (preclinical) · human benefits not established

⚠ Because CBG acts on the α2-adrenoceptor (involved in blood-pressure regulation), its cardiovascular effects in people are uncharacterised — anyone with blood-pressure concerns or on cardiovascular medication should consult a clinician first. (Not medical advice.)

Is there human evidence for CBGV or CBG?

Barely any. Controlled human data on CBG are scarce Low, and not one controlled human trial of CBGV appears in our registry No primary evidence. CBG's evidence base is mostly cells and animals; CBGV lacks even that. For now, what either does in people is catalogue in progress. (Not medical advice.)

Low (CBG) · No primary evidence (CBGV) · no establishing human trial in our registry · catalogue in progress

Are CBGV and CBG intoxicating, and are they legal?

CBG is non-intoxicating Established, and CBGV has no known intoxicating effect, though it has not been characterised in humans Low. On the law, both generally sit within the US hemp framework: under the 2018 Farm Bill, derivatives with no more than 0.3% Δ9-THC are broadly legal at the federal level, while state and product-class rules vary. Not legal advice.

Grade: Established (CBG non-intoxicating) · Legal snapshot: dated and jurisdiction-specific; check local law

Will CBGV or CBG show up on a drug test?

On their own they shouldn't: standard drug tests look for THC and its metabolite (THC-COOH), which leaves CBG and CBGV outside the net Established. The risk sits in the trace THC that full- or broad-spectrum products may carry, which can occasionally produce a positive. The product's COA shows how much THC is in the jar. (Not medical advice.)

Grade: Established (tests target THC) · caveat on THC in the product

Informational only — not our claims, and not advice

The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event: if you experienced a possible adverse effect from a cannabinoid product, please report it via the platform's "Report a safety event" path.

Verified anchors: Cascio 2010 (PMID 20002104 — CBG α2-adrenoceptor agonist / 5-HT1A antagonist / CB1 competitive antagonist, in vitro) · De Petrocellis 2011 (PMID 21175579 — CBG TRPV1/TRPV2 desensitiser; TRPM8 antagonist, in vitro) · Borrelli 2013 (PMID 23415610 — CBG in a murine colitis model, preclinical). CBGV pharmacology is catalogue-in-progress; marketed effects are attributed to third parties.

Before you act on what you have read

Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.

Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.

Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.

Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event →

Keep exploring

The compounds compared

More comparisons

All comparisons

Reference